Stockscreener 앱 받기
2.88
3.23%
0.09
전일 마감가:
$2.79
열려 있는:
$2.8
하루 거래량:
760.25K
Relative Volume:
0.86
시가총액:
$194.00M
수익:
$488.00K
순이익/손실:
$-41.44M
주가수익비율:
-3.0968
EPS:
-0.93
순현금흐름:
$-31.47M
1주 성능:
-6.49%
1개월 성능:
+20.00%
6개월 성능:
-34.84%
1년 성능:
-15.29%
1일 변동 폭
$2.78
$3.015
1주일 범위
$2.72
$3.08
52주 변동 폭
$1.90
$4.99
Cardiff Oncology Inc Stock (CRDF) Company Profile
명칭
Cardiff Oncology Inc
전화
858-952-7570
주소
11055 FLINTKOTE AVENUE, SAN DIEGO, CA
CRDF을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRDF
Cardiff Oncology Inc
|
2.88 | 187.94M | 488.00K | -41.44M | -31.47M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cardiff Oncology Inc Stock (CRDF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 개시 | Noble Capital Markets | Outperform |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2025-06-24 | 개시 | Jefferies | Hold |
| 2024-09-06 | 개시 | Craig Hallum | Buy |
| 2022-01-05 | 개시 | William Blair | Outperform |
| 2021-12-08 | 개시 | Robert W. Baird | Outperform |
| 2021-08-09 | 재개 | Maxim Group | Buy |
| 2020-10-22 | 개시 | H.C. Wainwright | Buy |
| 2020-10-08 | 개시 | Piper Sandler | Overweight |
모두보기
Cardiff Oncology Inc 주식(CRDF)의 최신 뉴스
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $11.13 Consensus Price Target from Brokerages - Defense World
Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured Enthusiasm (NASDAQ:CRDF) - Seeking Alpha
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Cardiff Oncology Inc. stock a buy for dividend growthJuly 2025 Action & Long Hold Capital Preservation Tips - Улправда
Aug Wrap: How Cardiff Oncology Inc XE7C stock reacts to Fed tightening2025 Breakouts & Breakdowns & Fast Gain Stock Tips - Bộ Nội Vụ
How Cardiff Oncology Inc. (XE7C) stock reacts to Fed tighteningRisk Management & Stepwise Swing Trade Plans - Улправда
Equities Analysts Issue Forecasts for CRDF Q4 Earnings - Defense World
Can Cardiff Oncology Inc. stock double in next 5 yearsDividend Growth Stocks & Today’s Picks, Tomorrow’s Winners - ulpravda.ru
Q4 Earnings Estimate for CRDF Issued By Noble Financial - MarketBeat
What is Noble Financial’s Estimate for CRDF FY2025 Earnings? - Defense World
Analysts Offer Predictions for CRDF FY2025 Earnings - MarketBeat
Cardiff Oncology stock initiated with Outperform rating by Noble Capital - Investing.com Australia
Noble Financial Initiates Coverage on Cardiff Oncology (NASDAQ:CRDF) - MarketBeat
Cardiff Oncology Inc. (CRDF) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Investors Purchase High Volume of Call Options on Cardiff Oncology (NASDAQ:CRDF) - Defense World
Cardiff Oncology (FRA:XE7C) EV-to-OCF : -3.04 (As of Dec. 24, 2025) - GuruFocus
Stock Traders Purchase High Volume of Cardiff Oncology Call Options (NASDAQ:CRDF) - MarketBeat
Flputnam Investment Management Co. Purchases 543,370 Shares of Cardiff Oncology, Inc. $CRDF - MarketBeat
Why analysts raise outlook for Cardiff Oncology Inc. (XE7C) stockTrade Analysis Report & Precise Swing Trade Entry Alerts - Улправда
3 Penny Stocks With At Least $100M Market Cap - simplywall.st
Short Covering: How analysts revise price targets for ConAgra Brands Inc stockPrice Action & Low Risk Profit Maximizing Plans - moha.gov.vn
Cardiff Oncology Earnings Notes - Trefis
Will Cardiff Oncology Inc. stock benefit from green energy trendsQuarterly Portfolio Summary & Verified Technical Trade Signals - Улправда
Quarterly Earnings: Will SIFYR stock continue dividend increasesMarket Activity Summary & AI Forecasted Entry and Exit Points - moha.gov.vn
Is Cardiff Oncology Inc. stock affected by interest rate hikesWeekly Profit Summary & Weekly Breakout Watchlists - Улправда
Would You Still Hold Cardiff Oncology Stock If It Fell 30%? - Trefis
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.83 Average Price Target from Analysts - Defense World
Published on: 2025-12-20 05:10:29 - Улправда
Institution Moves: Will Cardiff Oncology Inc. stock benefit from green energy trendsCPI Data & Daily Profit Focused Screening - Улправда
Aug Spikes: Is Cardiff Oncology Inc. stock affected by interest rate hikes2025 Retail Activity & Safe Swing Trade Setup Alerts - Улправда
Cardiff Oncology (CRDF) Reports Q1 Loss, Lags Revenue Estimates - sharewise.com
Cardiff Oncology (STU:XE7C) EV-to-FCF : -2.30 (As of Dec. 18, 2025) - GuruFocus
Can Cardiff Oncology Inc. stock sustain revenue growthJuly 2025 Momentum & Consistent Return Investment Signals - Улправда
Cardiff Oncology, Inc. (NASDAQ:CRDF) Given Average Rating of "Hold" by Brokerages - MarketBeat
Operating cash flow per share of Cardiff Oncology, Inc. – LSX:A2P4GU - TradingView — Track All Markets
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era - The Manila Times
Zacks Small Cap Weighs in on CRDF FY2025 Earnings - Defense World
What drives Cardiff Oncology Inc stock priceSmall Cap Stock Opportunities & Free Daily Stock Hotspot Analysis - earlytimes.in
Cardiff Oncology CRDF US - Smartkarma
FY2025 Earnings Forecast for CRDF Issued By Zacks Small Cap - MarketBeat
A new trading data show Cardiff Oncology Inc (CRDF) is showing positive returns. - setenews.com
Institutions profited after Cardiff Oncology, Inc.'s (NASDAQ:CRDF) market cap rose US$19m last week but retail investors profited the most - Yahoo Finance
CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response - Zacks Small Cap Research
Cardiff Presents Phase 1 Data Of Onvensertib In Chronic Myelomonocytic Leukemia At ASH 2025 - Nasdaq
Cardiff oncology reports positive results for onvansertib in leukemia trial - Investing.com
Cardiff oncology reports positive results for onvansertib in leukemia trial By Investing.com - Investing.com India
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 - The Manila Times
Cardiff Oncology Announces Clinical Data from - One News Page
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference - The Manila Times
Cardiff Oncology Inc (CRDF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Cardiff Oncology Inc 주식 (CRDF) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| PACE GARY W | Director |
Jul 30 '25 |
Buy |
2.45 |
15,000 |
36,750 |
1,345,676 |
4.73%
0.92%
자본화:
|
볼륨(24시간):